Clinical trials: Arterial Obstructive Diseases
Metabolic Syndrome
Effect of Aged Garlic Extract on Atherosclerosis
The investigators will be assessing the effect of Aged Garlic Extract on the coronary arteries. The investigators will enroll patients in a double blind study, where half the patients will receive placebo, and have the patients…
- Trial name
- Garlic4 (NCT01534910)
- Testing
- aged garlic extract
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Peripheral Artery Disease, Type 2 Diabetes
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period.
- Trial name
- NCT02325466
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease, Left Ventricular Dysfunction
Balloon Pump Assisted Coronary Intervention Study
This study will test the hypothesis that elective use of the Intra-Aortic Balloon Pump (IABP) in patients undergoing high-risk Percutaneous Coronary Intervention (PCI) will reduce the rate of in-hospital major adverse cardiac and…
- Trial name
- BCIS-1 (NCT00910481)
- Testing
- Intra-Aortic Balloon Pump
- Where
- United Kingdom
- Volunteers
- 301 people
- Sponsor
- British Cardiovascular Intervention Society
Atherosclerosis
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
- Trial name
- NCT00116831
- Testing
- Glipizide, rosiglitazone maleate
- Where
- 156 sites in United States, Argentina and 18 more
- Volunteers
- 672 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, Mild Cognitive Impairment
Genomic Outcomes of Metformin
Medical scientists have found that people with diabetes who take the drug Metformin have less age-related disease than those taking other treatments and researchers believe it may prevent numerous diseases and conditions that…
- Conditions
- Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
- Trial name
- GOMET (NCT02986659)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Osteoarthritis, Cardiovascular Disease
Risk Factor Control Before Orthopedic Surgery
This trial is designed to determine the best preoperative management strategy for patients undergoing orthopedic surgery.
- Trial name
- OPTMIZE-OS (NCT01837069)
- Testing
- Metoprolol, Lisinopril, Atorvastatin
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- NYU Langone Health
Coronary Artery Disease
HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography
To determine the diagnostic performance of FFRCT by coronary computed tomographic angiography (cCTA), as compared to cCTA alone, for non-invasive determination of the presence of a hemodynamically significant coronary lesion…
- Trial name
- HFNXT (NCT01757678)
- Testing
- ICA (Invasive Coronary Angiography), FFR (Fractional Flow Reserve), cCTA (coronary computed tomography angiography)
- Where
- Denmark
- Volunteers
- 276 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease
Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases
This is a multi-center, prospective, non-randomized, double-blinded trial to evaluate the sensitivity and specificity of the CADence device in detecting the existence of clinically significant coronary artery disease as…
- Trial name
- TURBULENCE (NCT01743040)
- Testing
- CADence
- Where
- 24 sites in United States
- Volunteers
- 1,014 people
- Sponsor
- AUM Cardiovascular, Inc.
Chronic Total Occlusion of Coronary Artery, Vascular Disease
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-AV DAPT (NCT01106534)
- Testing
- clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Where
- 144 sites in United States
- Volunteers
- 870 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
The purpose of this study is to determine if regadenoson is as safe and effective as adenosine when used in the cardiac catheterization lab during measurement of coronary flow reserve and fractional flow reserve.
- Trial name
- NCT01161121
- Testing
- adenosine, regadenoson
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- St. Louis University
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Myocardiopathies, Ischemia, Myocardial
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
- Conditions
- Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac
- Trial name
- EMMA (NCT00376532)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Coronary Artery Disease
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
The recommended antiplatelet treatment regimen for patients affected by acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the combination of aspirin and a P2Y12 receptor…
- Trial name
- SWAP-4 (NCT02287909)
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Florida
Dialysis, Cardiovascular Disease
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular disease including atherosclerotic cardiovascular disease.
- Conditions
- Dialysis, Cardiovascular Disease, Atherosclerosis, Inflammation
- Trial name
- NCT01159054
- Testing
- Extended Release Nicotinic Acid (Niaspan)
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Brigham and Women's Hospital
Coronary Artery Disease, Coronary Artery Chronic Total Occlusion
The Asahi Intecc PTCA Chronic Total Occlusion Study
The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or…
- Trial name
- CTO-PCI (NCT02379923)
- Testing
- Crossing of Coronary Artery CTO
- Where
- 12 sites in United States
- Volunteers
- 163 people
- Sponsor
- Asahi Intecc USA Inc
Peripheral Arterial Disease
Momentum-enabled Treadling Methodology to Improve Gait and Enhance Mobility
This is a pilot study of a new exercise device (TREDLR) designed to facilitate repetitive ankle flexion/extension movements (i.e., "treadling") through a momentum-driven internal flywheel while seated.
- Trial name
- NCT03891641
- Testing
- Treadwell Tredlr
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis, Coronary Artery Disease
PROMUS Element Japan Small Vessel Trial
A non-randomized, small vessel (SV) trial at approximately 15 sites in Japan to enroll 60 patients with a de novo lesion ≤28 mm in length (by visual estimate) in a native coronary artery ≥2.25 mm to <2.50 mm in diameter (by…
- Trial name
- NCT01080261
- Testing
- PROMUS Element
- Where
- 15 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
The hypothesis: Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
- Trial name
- REDUCED (NCT01031095)
- Testing
- coronary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Bursa Postgraduate Hospital
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN Sub-study
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01182428
- Testing
- XIENCE V®/ XIENCE PRIME™, CYPHER SELECT
- Where
- 25 sites in Argentina, Austria and 13 more
- Volunteers
- 455 people
- Sponsor
- Abbott Medical Devices